DE69229640D1 - Teilchen, methode zur herstellung der teilchen und deren verwendung - Google Patents

Teilchen, methode zur herstellung der teilchen und deren verwendung

Info

Publication number
DE69229640D1
DE69229640D1 DE69229640T DE69229640T DE69229640D1 DE 69229640 D1 DE69229640 D1 DE 69229640D1 DE 69229640 T DE69229640 T DE 69229640T DE 69229640 T DE69229640 T DE 69229640T DE 69229640 D1 DE69229640 D1 DE 69229640D1
Authority
DE
Germany
Prior art keywords
phase
particles
pct
homogeneous
date apr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69229640T
Other languages
English (en)
Other versions
DE69229640T2 (de
Inventor
Tomas Landh
Kare Larssons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandberg Development AB
Original Assignee
GS Development AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GS Development AB filed Critical GS Development AB
Priority claimed from PCT/SE1992/000692 external-priority patent/WO1993006921A1/en
Publication of DE69229640D1 publication Critical patent/DE69229640D1/de
Application granted granted Critical
Publication of DE69229640T2 publication Critical patent/DE69229640T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/02—Liquid crystal materials characterised by optical, electrical or physical properties of the components, in general
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K19/54—Additives having no specific mesophase characterised by their chemical composition
    • C09K19/542—Macromolecular compounds
    • C09K19/544—Macromolecular compounds as dispersing or encapsulating medium around the liquid crystal
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K2019/528—Surfactants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/90—Liquid crystal material of, or for, colloid system, e.g. g phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
DE69229640T 1991-10-04 1992-10-02 Teilchen, methode zur herstellung der teilchen und deren verwendung Expired - Lifetime DE69229640T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77101491A 1991-10-04 1991-10-04
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof

Publications (2)

Publication Number Publication Date
DE69229640D1 true DE69229640D1 (de) 1999-08-26
DE69229640T2 DE69229640T2 (de) 1999-12-16

Family

ID=25090424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229640T Expired - Lifetime DE69229640T2 (de) 1991-10-04 1992-10-02 Teilchen, methode zur herstellung der teilchen und deren verwendung

Country Status (10)

Country Link
US (1) US5531925A (de)
EP (1) EP0643620B1 (de)
JP (1) JP3571717B2 (de)
AT (1) ATE182278T1 (de)
AU (1) AU2699892A (de)
BR (1) BR9206593A (de)
CA (1) CA2120359C (de)
DE (1) DE69229640T2 (de)
ES (1) ES2133391T3 (de)
FI (1) FI941538A (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085827C (en) * 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JPH08254688A (ja) * 1995-03-16 1996-10-01 Toshiba Corp 液晶表示素子
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
AU714584B2 (en) 1995-07-21 2000-01-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0965336A1 (de) * 1995-11-09 1999-12-22 Microbiological Research Authority Mikroverkapselte DNA zur Gentherapie
US6284375B1 (en) * 1996-10-18 2001-09-04 Tuo Jin Lipid vesicle system
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6106609A (en) * 1997-04-08 2000-08-22 The United States Of America As Represented By The Secretary Of The Navy Formation of nanocrystalline semiconductor particles within a bicontinuous cubic phase
DE69710442T2 (de) * 1997-05-02 2002-10-02 Takasago Perfumery Co Ltd Flüssigkristallphase enthaltende Lipidzusammensetzung
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
AU747252B2 (en) 1997-09-09 2002-05-09 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
CA2342832A1 (en) * 1998-09-04 2000-03-16 Powderject Research Limited Immunodiagnostics using particle delivery methods
DE50008435D1 (de) * 1999-08-06 2004-12-02 Max Delbrueck Centrum Implantierbares wirkstoffdepot
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
AU1987802A (en) * 2000-11-29 2002-06-11 Lyotropic Therapeutics Llc Solvent systems for pharmaceutical agents
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030060695A1 (en) * 2001-03-07 2003-03-27 Connelly Patrick R. Implantable artificial organ devices
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
US20040022820A1 (en) * 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
US20050238724A1 (en) * 2002-04-23 2005-10-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
EP1534512A4 (de) * 2002-06-13 2009-04-29 Lyotropic Therapeutics Inc Beschichtete teilchen, herstellungs- und verwendungsverfahren
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005014162A1 (en) * 2003-08-04 2005-02-17 Camurus Ab Method for improving the properties of amphiphile particles
EP1667656A4 (de) * 2003-09-01 2011-12-28 Mayne Pharma Int Pty Ltd Zusammensetzungen und verfahren zur abgabe von biologisch wirksamen mitteln
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
BRPI0414321B8 (pt) 2003-09-22 2021-06-22 Baxter Healthcare Sa esterilização à alta pressão para esterilização final de preparações farmacêuticas e produtos médicos
US20070293441A1 (en) * 2003-09-22 2007-12-20 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
PL1682091T3 (pl) * 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
US8182834B2 (en) 2004-01-23 2012-05-22 Camurus Ab Ternary non-lamellar lipid compositions
GB0401513D0 (en) * 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1598060A1 (de) * 2004-05-18 2005-11-23 Nestec S.A. Öl-in-Wasser-Emulsion für Lieferung
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
WO2006013369A2 (en) * 2004-08-04 2006-02-09 Camurus Ab Compositions forming non-lamellar dispersions
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8871712B2 (en) * 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
EP1843746B1 (de) * 2005-01-14 2011-03-16 Camurus Ab Somatostatin-analog-formulierungen
DK1845942T3 (da) 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
JP5127466B2 (ja) * 2005-01-21 2013-01-23 カムルス エービー 医薬脂質組成物
GB0501364D0 (en) * 2005-01-21 2005-03-02 Camurus Ab Compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
US20100047413A1 (en) * 2006-09-15 2010-02-25 Cabalka Tourtellotte Leanne M Method of using amphiphilic multiblock copolymers in food
CZ299218B6 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2393472B1 (de) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
US9080973B2 (en) * 2009-04-22 2015-07-14 Wisconsin Alumni Research Foundation Analyte detection using liquid crystals
CA2871821C (en) * 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
MX350964B (es) 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
JP6655548B2 (ja) 2014-03-25 2020-02-26 ジェネンテック， インコーポレイテッド 細胞培養培地における使用のためのポロキサマーを調製する方法
EP3212173A4 (de) 2014-10-30 2018-06-20 Textile-Based Delivery, Inc. Verabreichungssysteme
US20210275489A1 (en) 2018-06-21 2021-09-09 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
WO2021158517A1 (en) * 2020-02-03 2021-08-12 Curemast, Inc. Compositions and methods of use thereof for treatment of mastitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4556289A (en) * 1983-03-21 1985-12-03 Manchester R & D Partnership Low birefringence encapsulated liquid crystal and optical shutter using same
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
GB8803037D0 (en) * 1988-02-10 1988-03-09 Unilever Plc Aqueous detergent compositions & methods of forming them
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
JPH03139525A (ja) * 1989-10-24 1991-06-13 Sunstar Eng Inc 紫外線硬化性組成物

Also Published As

Publication number Publication date
EP0643620A1 (de) 1995-03-22
EP0643620B1 (de) 1999-07-21
DE69229640T2 (de) 1999-12-16
ATE182278T1 (de) 1999-08-15
FI941538A (fi) 1994-05-31
BR9206593A (pt) 1995-11-28
CA2120359C (en) 2000-12-26
US5531925A (en) 1996-07-02
JP3571717B2 (ja) 2004-09-29
JPH07502197A (ja) 1995-03-09
AU2699892A (en) 1993-05-03
CA2120359A1 (en) 1993-04-15
ES2133391T3 (es) 1999-09-16
FI941538A0 (fi) 1994-03-31

Similar Documents

Publication Publication Date Title
ATE182278T1 (de) Teilchen, methode zur herstellung der teilchen und deren verwendung
NO941191L (no) Partikler, fremgangsmåte for fremstilling samt anvendelse av slike
DE69202207D1 (de) Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan.
DE69425671D1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
KR950703954A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 릴루졸의 적용(application of riluzole in the treatment of neurological lesions related to traumatic injuries)
FR05C0045I2 (de)
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
GB9203037D0 (en) Contrast agents
PL307914A1 (en) Lipopetide derivatives, method of obtaining them and therapeutic agents containing such compounds
AU6194286A (en) New carboxylic acid derivatives, their manufacturing process,use and medicines containing these compounds
IL106121A0 (en) Dna sequences with oligosaccharide transporter,plasmids,bacteria and plants containing a transporter as well as a process for the preparation and transformation of yeast strains for identification of the transporter
EP0137441A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
ATE59757T1 (de) Phospholipidhaltige produkte, deren herstellung und verwendung.
ATE143801T1 (de) Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und verfahren zur herstellung derselben
GR3026324T3 (en) Use of prostacyclin derivatives to prevent or treat disorders of the microcirculating system when x-ray, nmr or ultrasonic contrasting agents are administered.
FR2725718B1 (fr) Bis-2-aminopyridines, leur procede de preparation et leurs applications
NO307933B1 (no) Vann-uløselig eller lite vannløselig terapeutisk forbindelse, anvendelse derav samt farmasøytisk blanding inneholdende nevnte forbindelse
DE3881484T2 (de) Optisch aktive Produkte von 20,21-Dinoreburnamenin-Derivaten, Verfahren zur Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
GB2349335A (en) Compositions
EP0379132A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
IL107917A0 (en) Triazoloquinazolines, their preparation and their use as medicaments
ATE150026T1 (de) Benzo(f>chinoxalindionderivative, deren herstellung und verwendung in arzneimitteln
HUT70477A (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments contg. them cont. the same
EP0281092A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
NO964905D0 (no) Substituerte benzendikarboksylsyre-diguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen

Legal Events

Date Code Title Description
R071 Expiry of right

Ref document number: 643620

Country of ref document: EP